This article is more than 5 years old. Information may no longer be current.
Sanofi’s insulin-GLP-1 combination drug now available in US
Click Here to Manage Email Alerts
Sanofi’s fixed-ratio combination of insulin glargine and lixisenatide is now available by prescription in the U.S. for the treatment of type 2 diabetes.
Soliqua 100/33, approved by the FDA in November, is a once-daily injection of insulin glargine (Lantus) and the GLP-1 receptor agonist lixisenatide and is intended for the treatment of adults with type 2 diabetes who are inadequately controlled on basal insulin or lixisenatide.
In the labeled clinical trial, patients assigned to Soliqua 100/33 saw a greater decrease in HbA1c from baseline to week 30 vs. insulin glargine alone.
The most frequently reported adverse events included hypoglycemia, as well as nausea (10%), nasopharyngitis (7%), diarrhea (7%) and upper respiratory tract infection (5%).
“We are encouraged by the potential of Soliqua 100/33, which has demonstrated superior HbA1c lowering versus Lantus,” Peter Guenter, executive vice president and head of the global diabetes and cardiovascular business unit at Sanofi, said in the release. “By offering Soliqua 100/33 ... at a competitive price while facilitating patient access, we believe we are providing value to patients and the health care system.”
Sanofi is also offering a support program called Soliqua 100/33 COACH, which is free to adults with type 2 diabetes being prescribed Soliqua 100/33.